Loading…

Hepatic‐Targeted Nano‐enzyme with Resveratrol Loading for Precise Relief of Nonalcoholic Steatohepatitis

Nonalcoholic steatohepatitis (NASH) is characterized by massive lipid deposition in hepatocytes and is often associated with hepatic inflammation and other severe metabolic syndromes. The intervention of NASH can prevent its further progression into hepatocarcinoma. In this study we have successfull...

Full description

Saved in:
Bibliographic Details
Published in:ChemMedChem 2023-03, Vol.18 (5), p.e202200468-n/a
Main Authors: Tong, Yili, Yu, Xiaofeng, Huang, Yiqin, Zhang, Ziyan, Mi, Lin, Bao, Zhijun
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3738-e49391e4cbf3c5469d984adf2a3102969f122b5dc1f87cf56fcf64d2dc66891a3
cites cdi_FETCH-LOGICAL-c3738-e49391e4cbf3c5469d984adf2a3102969f122b5dc1f87cf56fcf64d2dc66891a3
container_end_page n/a
container_issue 5
container_start_page e202200468
container_title ChemMedChem
container_volume 18
creator Tong, Yili
Yu, Xiaofeng
Huang, Yiqin
Zhang, Ziyan
Mi, Lin
Bao, Zhijun
description Nonalcoholic steatohepatitis (NASH) is characterized by massive lipid deposition in hepatocytes and is often associated with hepatic inflammation and other severe metabolic syndromes. The intervention of NASH can prevent its further progression into hepatocarcinoma. In this study we have successfully constructed liver‐targeted Ce‐based hollow mesoporous nanocarriers loaded with bioactive drugs. This may provide an effective approach for eliminating NASH. Liver‐section‐specific targeting was realized by covalently linked galactose (Gal), which can be specifically recognized by receptors in the membranes of hepatocytes. Meanwhile, resveratrol (Res), a drug used to treat NASH, was efficiently loaded into the pores and cavity of CeO2 (Res@H−CeO2−Gal). In steatotic HepG2 cells (free fatty acid induction), this nanosystem was found to enhance cellular Res internalization for improved anti‐lipogenesis activity. In mice with NASH, Res@H−CeO2−Gal increased Res delivery to liver sections for a reduction in lipid accumulation and enhanced anti‐inflammatory activity from the antioxidant capacity of Ce‐based nanocarriers. This effectively recovered NASH mice to the normal state. These findings show that the hepatic targeting and Res delivery nanoplatform could act as a safe and promising strategy for the elimination of NASH and other liver diseases. Nonalcoholic steatohepatitis (NASH) causes liver inflammation and other severe metabolic syndromes, and can eventually give rise to hepatocarcinoma. We constructed liver‐targeted Ce‐based hollow mesoporous nanocarriers loaded with bioactive drugs. Liver‐specific targeting was realized by covalently linked galactose (Gal), while resveratrol (Res) was loaded into the pores and cavity of CeO2 (Res@H−CeO2−Gal). This nanosystem was found to enhance cellular Res internalization for improved anti‐lipogenesis activity. These findings reveal a safe and promising strategy for the elimination of NASH and other liver diseases.
doi_str_mv 10.1002/cmdc.202200468
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2737117547</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2781077937</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3738-e49391e4cbf3c5469d984adf2a3102969f122b5dc1f87cf56fcf64d2dc66891a3</originalsourceid><addsrcrecordid>eNqF0ctOGzEYBWCrApVLu-2yssSGTVJfJr4sUbhKKVQtXY8c-zcx8oyDPQGFVR-hz9gn6YRAkNiwsi1_PpZ9EPpCyZASwr7ZxtkhI4wRUgn1Ae1SJchAUiW3NnOpd9BeKbc9qRRVH9EOF1wRrvUuiucwN12w__78vTb5Bjpw-NK0qV9D-7hsAD-EboZ_QrmHbLqcIp4k40J7g33K-EcGGwr0-zGAx8njy9SaaNMsxWDxrw5Ml2ZPV3ShfELb3sQCn5_HffT79OR6fD6YXJ1djI8mA8slVwOoNNcUKjv13I4qoZ1WlXGeGU4J00J7yth05Cz1Slo_Et56UTnmrBBKU8P30eE6d57T3QJKVzehWIjRtJAWpWaSS0rlqJI9PXhDb9Mi909YKUWJlJqv1HCtbE6lZPD1PIfG5GVNSb3qoV71UG966A98fY5dTBtwG_7y8T3Qa_AQIizfiavH34_Hr-H_AU2glyw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2781077937</pqid></control><display><type>article</type><title>Hepatic‐Targeted Nano‐enzyme with Resveratrol Loading for Precise Relief of Nonalcoholic Steatohepatitis</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Tong, Yili ; Yu, Xiaofeng ; Huang, Yiqin ; Zhang, Ziyan ; Mi, Lin ; Bao, Zhijun</creator><creatorcontrib>Tong, Yili ; Yu, Xiaofeng ; Huang, Yiqin ; Zhang, Ziyan ; Mi, Lin ; Bao, Zhijun</creatorcontrib><description>Nonalcoholic steatohepatitis (NASH) is characterized by massive lipid deposition in hepatocytes and is often associated with hepatic inflammation and other severe metabolic syndromes. The intervention of NASH can prevent its further progression into hepatocarcinoma. In this study we have successfully constructed liver‐targeted Ce‐based hollow mesoporous nanocarriers loaded with bioactive drugs. This may provide an effective approach for eliminating NASH. Liver‐section‐specific targeting was realized by covalently linked galactose (Gal), which can be specifically recognized by receptors in the membranes of hepatocytes. Meanwhile, resveratrol (Res), a drug used to treat NASH, was efficiently loaded into the pores and cavity of CeO2 (Res@H−CeO2−Gal). In steatotic HepG2 cells (free fatty acid induction), this nanosystem was found to enhance cellular Res internalization for improved anti‐lipogenesis activity. In mice with NASH, Res@H−CeO2−Gal increased Res delivery to liver sections for a reduction in lipid accumulation and enhanced anti‐inflammatory activity from the antioxidant capacity of Ce‐based nanocarriers. This effectively recovered NASH mice to the normal state. These findings show that the hepatic targeting and Res delivery nanoplatform could act as a safe and promising strategy for the elimination of NASH and other liver diseases. Nonalcoholic steatohepatitis (NASH) causes liver inflammation and other severe metabolic syndromes, and can eventually give rise to hepatocarcinoma. We constructed liver‐targeted Ce‐based hollow mesoporous nanocarriers loaded with bioactive drugs. Liver‐specific targeting was realized by covalently linked galactose (Gal), while resveratrol (Res) was loaded into the pores and cavity of CeO2 (Res@H−CeO2−Gal). This nanosystem was found to enhance cellular Res internalization for improved anti‐lipogenesis activity. These findings reveal a safe and promising strategy for the elimination of NASH and other liver diseases.</description><identifier>ISSN: 1860-7179</identifier><identifier>EISSN: 1860-7187</identifier><identifier>DOI: 10.1002/cmdc.202200468</identifier><identifier>PMID: 36380399</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>Animals ; Cerium oxides ; drug delivery ; Fatty acids ; Galactose ; hepatic targeting ; Hepatocytes ; Inflammation ; Internalization ; lipid accumulation ; Lipids ; Lipids - pharmacology ; Lipogenesis ; Liver ; Liver - metabolism ; Liver diseases ; mesoporous CeO2 ; Metabolic disorders ; Metabolic syndrome ; Mice ; Mice, Inbred C57BL ; Non-alcoholic Fatty Liver Disease - metabolism ; Resveratrol ; Resveratrol - metabolism ; Resveratrol - pharmacology ; Resveratrol - therapeutic use</subject><ispartof>ChemMedChem, 2023-03, Vol.18 (5), p.e202200468-n/a</ispartof><rights>2022 Wiley‐VCH GmbH</rights><rights>2022 Wiley-VCH GmbH.</rights><rights>2023 Wiley‐VCH GmbH</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3738-e49391e4cbf3c5469d984adf2a3102969f122b5dc1f87cf56fcf64d2dc66891a3</citedby><cites>FETCH-LOGICAL-c3738-e49391e4cbf3c5469d984adf2a3102969f122b5dc1f87cf56fcf64d2dc66891a3</cites><orcidid>0000-0002-1382-5306</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36380399$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tong, Yili</creatorcontrib><creatorcontrib>Yu, Xiaofeng</creatorcontrib><creatorcontrib>Huang, Yiqin</creatorcontrib><creatorcontrib>Zhang, Ziyan</creatorcontrib><creatorcontrib>Mi, Lin</creatorcontrib><creatorcontrib>Bao, Zhijun</creatorcontrib><title>Hepatic‐Targeted Nano‐enzyme with Resveratrol Loading for Precise Relief of Nonalcoholic Steatohepatitis</title><title>ChemMedChem</title><addtitle>ChemMedChem</addtitle><description>Nonalcoholic steatohepatitis (NASH) is characterized by massive lipid deposition in hepatocytes and is often associated with hepatic inflammation and other severe metabolic syndromes. The intervention of NASH can prevent its further progression into hepatocarcinoma. In this study we have successfully constructed liver‐targeted Ce‐based hollow mesoporous nanocarriers loaded with bioactive drugs. This may provide an effective approach for eliminating NASH. Liver‐section‐specific targeting was realized by covalently linked galactose (Gal), which can be specifically recognized by receptors in the membranes of hepatocytes. Meanwhile, resveratrol (Res), a drug used to treat NASH, was efficiently loaded into the pores and cavity of CeO2 (Res@H−CeO2−Gal). In steatotic HepG2 cells (free fatty acid induction), this nanosystem was found to enhance cellular Res internalization for improved anti‐lipogenesis activity. In mice with NASH, Res@H−CeO2−Gal increased Res delivery to liver sections for a reduction in lipid accumulation and enhanced anti‐inflammatory activity from the antioxidant capacity of Ce‐based nanocarriers. This effectively recovered NASH mice to the normal state. These findings show that the hepatic targeting and Res delivery nanoplatform could act as a safe and promising strategy for the elimination of NASH and other liver diseases. Nonalcoholic steatohepatitis (NASH) causes liver inflammation and other severe metabolic syndromes, and can eventually give rise to hepatocarcinoma. We constructed liver‐targeted Ce‐based hollow mesoporous nanocarriers loaded with bioactive drugs. Liver‐specific targeting was realized by covalently linked galactose (Gal), while resveratrol (Res) was loaded into the pores and cavity of CeO2 (Res@H−CeO2−Gal). This nanosystem was found to enhance cellular Res internalization for improved anti‐lipogenesis activity. These findings reveal a safe and promising strategy for the elimination of NASH and other liver diseases.</description><subject>Animals</subject><subject>Cerium oxides</subject><subject>drug delivery</subject><subject>Fatty acids</subject><subject>Galactose</subject><subject>hepatic targeting</subject><subject>Hepatocytes</subject><subject>Inflammation</subject><subject>Internalization</subject><subject>lipid accumulation</subject><subject>Lipids</subject><subject>Lipids - pharmacology</subject><subject>Lipogenesis</subject><subject>Liver</subject><subject>Liver - metabolism</subject><subject>Liver diseases</subject><subject>mesoporous CeO2</subject><subject>Metabolic disorders</subject><subject>Metabolic syndrome</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Non-alcoholic Fatty Liver Disease - metabolism</subject><subject>Resveratrol</subject><subject>Resveratrol - metabolism</subject><subject>Resveratrol - pharmacology</subject><subject>Resveratrol - therapeutic use</subject><issn>1860-7179</issn><issn>1860-7187</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqF0ctOGzEYBWCrApVLu-2yssSGTVJfJr4sUbhKKVQtXY8c-zcx8oyDPQGFVR-hz9gn6YRAkNiwsi1_PpZ9EPpCyZASwr7ZxtkhI4wRUgn1Ae1SJchAUiW3NnOpd9BeKbc9qRRVH9EOF1wRrvUuiucwN12w__78vTb5Bjpw-NK0qV9D-7hsAD-EboZ_QrmHbLqcIp4k40J7g33K-EcGGwr0-zGAx8njy9SaaNMsxWDxrw5Ml2ZPV3ShfELb3sQCn5_HffT79OR6fD6YXJ1djI8mA8slVwOoNNcUKjv13I4qoZ1WlXGeGU4J00J7yth05Cz1Slo_Et56UTnmrBBKU8P30eE6d57T3QJKVzehWIjRtJAWpWaSS0rlqJI9PXhDb9Mi909YKUWJlJqv1HCtbE6lZPD1PIfG5GVNSb3qoV71UG966A98fY5dTBtwG_7y8T3Qa_AQIizfiavH34_Hr-H_AU2glyw</recordid><startdate>20230301</startdate><enddate>20230301</enddate><creator>Tong, Yili</creator><creator>Yu, Xiaofeng</creator><creator>Huang, Yiqin</creator><creator>Zhang, Ziyan</creator><creator>Mi, Lin</creator><creator>Bao, Zhijun</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1382-5306</orcidid></search><sort><creationdate>20230301</creationdate><title>Hepatic‐Targeted Nano‐enzyme with Resveratrol Loading for Precise Relief of Nonalcoholic Steatohepatitis</title><author>Tong, Yili ; Yu, Xiaofeng ; Huang, Yiqin ; Zhang, Ziyan ; Mi, Lin ; Bao, Zhijun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3738-e49391e4cbf3c5469d984adf2a3102969f122b5dc1f87cf56fcf64d2dc66891a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Animals</topic><topic>Cerium oxides</topic><topic>drug delivery</topic><topic>Fatty acids</topic><topic>Galactose</topic><topic>hepatic targeting</topic><topic>Hepatocytes</topic><topic>Inflammation</topic><topic>Internalization</topic><topic>lipid accumulation</topic><topic>Lipids</topic><topic>Lipids - pharmacology</topic><topic>Lipogenesis</topic><topic>Liver</topic><topic>Liver - metabolism</topic><topic>Liver diseases</topic><topic>mesoporous CeO2</topic><topic>Metabolic disorders</topic><topic>Metabolic syndrome</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Non-alcoholic Fatty Liver Disease - metabolism</topic><topic>Resveratrol</topic><topic>Resveratrol - metabolism</topic><topic>Resveratrol - pharmacology</topic><topic>Resveratrol - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tong, Yili</creatorcontrib><creatorcontrib>Yu, Xiaofeng</creatorcontrib><creatorcontrib>Huang, Yiqin</creatorcontrib><creatorcontrib>Zhang, Ziyan</creatorcontrib><creatorcontrib>Mi, Lin</creatorcontrib><creatorcontrib>Bao, Zhijun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>ChemMedChem</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tong, Yili</au><au>Yu, Xiaofeng</au><au>Huang, Yiqin</au><au>Zhang, Ziyan</au><au>Mi, Lin</au><au>Bao, Zhijun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatic‐Targeted Nano‐enzyme with Resveratrol Loading for Precise Relief of Nonalcoholic Steatohepatitis</atitle><jtitle>ChemMedChem</jtitle><addtitle>ChemMedChem</addtitle><date>2023-03-01</date><risdate>2023</risdate><volume>18</volume><issue>5</issue><spage>e202200468</spage><epage>n/a</epage><pages>e202200468-n/a</pages><issn>1860-7179</issn><eissn>1860-7187</eissn><abstract>Nonalcoholic steatohepatitis (NASH) is characterized by massive lipid deposition in hepatocytes and is often associated with hepatic inflammation and other severe metabolic syndromes. The intervention of NASH can prevent its further progression into hepatocarcinoma. In this study we have successfully constructed liver‐targeted Ce‐based hollow mesoporous nanocarriers loaded with bioactive drugs. This may provide an effective approach for eliminating NASH. Liver‐section‐specific targeting was realized by covalently linked galactose (Gal), which can be specifically recognized by receptors in the membranes of hepatocytes. Meanwhile, resveratrol (Res), a drug used to treat NASH, was efficiently loaded into the pores and cavity of CeO2 (Res@H−CeO2−Gal). In steatotic HepG2 cells (free fatty acid induction), this nanosystem was found to enhance cellular Res internalization for improved anti‐lipogenesis activity. In mice with NASH, Res@H−CeO2−Gal increased Res delivery to liver sections for a reduction in lipid accumulation and enhanced anti‐inflammatory activity from the antioxidant capacity of Ce‐based nanocarriers. This effectively recovered NASH mice to the normal state. These findings show that the hepatic targeting and Res delivery nanoplatform could act as a safe and promising strategy for the elimination of NASH and other liver diseases. Nonalcoholic steatohepatitis (NASH) causes liver inflammation and other severe metabolic syndromes, and can eventually give rise to hepatocarcinoma. We constructed liver‐targeted Ce‐based hollow mesoporous nanocarriers loaded with bioactive drugs. Liver‐specific targeting was realized by covalently linked galactose (Gal), while resveratrol (Res) was loaded into the pores and cavity of CeO2 (Res@H−CeO2−Gal). This nanosystem was found to enhance cellular Res internalization for improved anti‐lipogenesis activity. These findings reveal a safe and promising strategy for the elimination of NASH and other liver diseases.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>36380399</pmid><doi>10.1002/cmdc.202200468</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-1382-5306</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1860-7179
ispartof ChemMedChem, 2023-03, Vol.18 (5), p.e202200468-n/a
issn 1860-7179
1860-7187
language eng
recordid cdi_proquest_miscellaneous_2737117547
source Wiley-Blackwell Read & Publish Collection
subjects Animals
Cerium oxides
drug delivery
Fatty acids
Galactose
hepatic targeting
Hepatocytes
Inflammation
Internalization
lipid accumulation
Lipids
Lipids - pharmacology
Lipogenesis
Liver
Liver - metabolism
Liver diseases
mesoporous CeO2
Metabolic disorders
Metabolic syndrome
Mice
Mice, Inbred C57BL
Non-alcoholic Fatty Liver Disease - metabolism
Resveratrol
Resveratrol - metabolism
Resveratrol - pharmacology
Resveratrol - therapeutic use
title Hepatic‐Targeted Nano‐enzyme with Resveratrol Loading for Precise Relief of Nonalcoholic Steatohepatitis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T07%3A57%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatic%E2%80%90Targeted%20Nano%E2%80%90enzyme%20with%20Resveratrol%20Loading%20for%20Precise%20Relief%20of%20Nonalcoholic%20Steatohepatitis&rft.jtitle=ChemMedChem&rft.au=Tong,%20Yili&rft.date=2023-03-01&rft.volume=18&rft.issue=5&rft.spage=e202200468&rft.epage=n/a&rft.pages=e202200468-n/a&rft.issn=1860-7179&rft.eissn=1860-7187&rft_id=info:doi/10.1002/cmdc.202200468&rft_dat=%3Cproquest_cross%3E2781077937%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3738-e49391e4cbf3c5469d984adf2a3102969f122b5dc1f87cf56fcf64d2dc66891a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2781077937&rft_id=info:pmid/36380399&rfr_iscdi=true